跳至主要内容

MedPath Trial Home

机构资讯 AI 研究

数据来源：ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

搜索试验。追踪管线。洞察审批。由 AI 驱动的临床研究情报平台。

产品

临床试验
药物情报
全球审批
深度研究
价格方案

资源

常见问题
搜索

公司

资讯
关于我们
联系我们

法律

隐私政策
服务条款

免责声明： 本网站提供信息检索和数据分析服务。内容不构成医疗建议。适应性评估仅供参考，不能替代合格医疗专业人员的咨询。数据来源于公共注册库和监管机构；MedPath 不保证数据的完整性或准确性。请以原始资料为准。

© 2026 MedPath Trial 版权所有

服务条款隐私政策

我们重视您的隐私

我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。

Octapharma Pharmazeutika Produktionsgesellschaft Mbh

首页临床试验发起方与机构Octapharma Pharmazeutika Produktionsgesellschaft Mbh

Octapharma Pharmazeutika Produktionsgesellschaft Mbh

ACTIVE

奥地利www.octapharma.comSubsidiary

隶属于 Octapharma Ag

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

相关临床试验

8

3 进行中

药物批准

0

批准总数

监管机构

0

监管机构数

成立时间

N/A

概览

试验阶段分布

阶段

试验数

占比

1 期

4

50.0%

3 期

4

50.0%

试验状态分布

进行中（未招募）

3

37.5%

已完成

1

12.5%

招募中

4

50.0%

相关临床试验

该机构主办的试验（8）

Double-blind (neither the patient nor the doctor knows treatment allocation of the patient), randomized, placebo-controlled, prospective phase III clinical study to evaluate the efficacy and safety of Panzyga in infection prevention in patients with a specific type of cancer, cancer of the blood and bone marrow (Chronic Lymphocytic Leukemia) ("PRO-SID" study).

182 名受试者

A superiority study to compare the effect of Panzyga versus placebo in patients with pediatric acute-onset neuropsychiatric syndrome

40 名受试者

Prospective, open-label, single-arm, multicentre Phase 3 study to evaluate the pharmacokinetics, efficacy, tolerability, and safety of subcutaneous human immunoglobulin (Newnorm) in patients with primary immunodeficiency diseases

50 名受试者

Supporting weak immune system during autoimmune therapy: testing Panzyga to prevent infections

May 2026215 名受试者

Prospective, open-label, single-arm, multicentre Phase 3 study to evaluate the pharmacokinetics, efficacy, tolerability, and safety of subcutaneous human immunoglobulin (Newnorm) in patients with primary immunodeficiency diseases

进行中（未招募）

Jun 202472 名受试者

A superiority study to compare the effect of Panzyga versus placebo in patients with pediatric acute-onset neuropsychiatric syndrome

进行中（未招募）

Apr 202492 名受试者

Double-blind (neither the patient nor the doctor knows treatment allocation of the patient), randomized, placebo-controlled, prospective phase III clinical study to evaluate the efficacy and safety of Panzyga in infection prevention in patients with a specific type of cancer, cancer of the blood and bone marrow (Chronic Lymphocytic Leukemia) (PRO-SID study).

Dec 2023240 名受试者

Prospective, multicenter, randomized, double-blind, parallel group, placebo-controlled, efficacy and safety phase 3 study of an intravenous human plasma-derived C1 esterase inhibitor (C1-INH) concentrate in participants with congenital C1-INH deficiency for the treatment and pre-procedure prevention of acute hereditary angioedema attacks

进行中（未招募）

Oct 2023124 名受试者

药物批准

暂无批准数据

资讯

暂无资讯文章

本页目录

概览
相关临床试验8
药物批准
资讯

返回机构列表